$QURE News

Uniqure Stock Falls After Its Huntington's Gene Therapy Lands At The FDA

uniQure stock jumps as FDA accepts Huntington’s therapy filing

uniQure Announces FDA Acceptance and Priority Review of the Biologics License Application for ifezuntirgene inilparvovec for the Treatment of Huntington’s Disease

uniQure (QURE) Stock Could Be Overvalued Despite A Securities Investigation

uniQure to Announce Third Quarter 2026 Financial Results

uniQure: The Market Graded The Wrong Exam

Why uniQure (QURE) Is Down 5.9% After Fresh Huntington’s Gene Therapy Data Update And What’s Next

Barclays Downgrades uniQure to Equal-Weight, Lowers Price Target to $28

RBC Capital Maintains Outperform on uniQure, Lowers Price Target to $48

uniQure (QURE) Faces A Fresh AMT 130 Test After Mixed Data, Bargain Or Trap

uniQure Stock Crashed on Its Huntington’s Data. Wall Street’s Price Target Says the Selloff Went Too Far

uniQure: A Speculative Buy After Huntington's Disease Trial's 4-Year Data Update

Goldman Sachs Maintains Neutral on uniQure, Lowers Price Target to $31

uniQure Stock Plunges On 4-Year Data, But The Approval Path Is Intact (Rating Upgrade)

QURE Stock Clocks Worst Day In Over 10 Months: Four-Year Huntington’s Data Spooks Investors Despite Stronger Three-Year Filing Data

Uniqure Plummets 37% On Another Shocking Twist For Its Huntington's Drug

uniQure BLA Filed as AMT-130 Shows 4-Year Huntington’s Functional Benefit

uniQure N.V. (QURE) Discusses Additional Data from Phase I/II AMT-130 Study in Huntington's Disease Highlighting Disease Progression Slowing Transcript

uniQure: Another Selloff On 48-Month Huntington Data; I Am (Marginally) Bullish

Why Is uniQure Stock Sinking on Tuesday?